← Eichor
Condition: Angioedema Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Angioedema

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Tre
Phase 3 · 23 location(s) · Octapharma · NCT06361537Deep Phenotyping of CIndU
Phase N/A · 3 location(s) · Centre for Human Drug Research, Netherlands · NCT07359430STOP-HAE: A Phase 3 Study of ADX-324 in HAE
Phase 3 · 51 location(s) · ADARx Pharmaceuticals, Inc. · NCT06960213Deployment o the Multidisciplinary Prospective Cohort Imminent
NA · 1 location(s) · University Hospital, Lille · NCT04334031Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema
Phase 3 · 32 location(s) · Pharvaris Netherlands B.V. · NCT07266805Bradykinin-degradating Enzymes Activities in Angiotensin-Converting Enzyme Inhibitors-associated Angioedema
Phase N/A · 4 location(s) · University Hospital, Grenoble · NCT04763577Allergy and Immunology Natural History Study
Phase N/A · 1 location(s) · Columbia University · NCT05584488Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in
Phase 3 · 62 location(s) · Pharvaris Netherlands B.V. · NCT06679881A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema
NA · 1 location(s) · Takeda · NCT07293364A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of Saudi Arabia
Phase N/A · 1 location(s) · Takeda · NCT07263685Lanadelumab in Long-term Prophylaxis of Acquired Angioedema
Phase 4 · 1 location(s) · Bernstein Clinical Research Center · NCT06818474Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE
Phase 2 · 4 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT06919003A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)
Phase N/A · 22 location(s) · CSL Behring · NCT07001280Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients
Phase 1/Phase 2 · 1 location(s) · Institute for Asthma and Allergy · NCT07046806Donidalorsen Treatment in Children With Hereditary Angioedema
Phase 3 · 10 location(s) · Ionis Pharmaceuticals, Inc. · NCT07298447Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdema
Phase N/A · 1 location(s) · Istituti Clinici Scientifici Maugeri SpA · NCT07448181Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases
Phase N/A · 6 location(s) · Santé Arménie French-Armenian Research Center · NCT05904301Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
Phase 3 · 48 location(s) · ADARx Pharmaceuticals, Inc. · NCT07428499SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
Phase N/A · 8 location(s) · Leiden University Medical Center · NCT07021495CLOUD-R HAE REGISTRY
Phase N/A · 1 location(s) · University Hospital, Grenoble · NCT03845946ScATtEred Rare Disease Biobanks: a Model of Sample/Data Collection With susTainablE and Shared Criteria
Phase N/A · 1 location(s) · IRCCS Policlinico S. Donato · NCT06782230Institutional Registry of Rare Diseases
Phase N/A · 1 location(s) · Hospital Italiano de Buenos Aires · NCT06573723
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.